Aroa Biosurgery Ltd (ASX: ARX) Share Price and News

Mr Diddams is a resident of Australia and has over forty years of experience as a CFO, CEO and director of both private and publicly listed companies. John has knowledge and experience in the practical application of ASX Listing Rules, Australian corporations' law, international accounting standards and corporate governance principles. He heads a CPA firm providing corporate advisory services to SME and mid-cap companies and has managed the listing process, secondary capital raisings and ASX listings in several diverse industry sectors, including oil and gas, food and retail, telecommunications, adventure tourism, biotechnology, and the dental and medical sectors

Mr McCaw is a resident of New Zealand and is the Founding Partner of Movac. He led the original investment round into AROA in 2008, has worked closely with the Company and has served on the Board since then. He is currently the Executive Chair and CEO of Docuvera, a software company that delivers component authoring solutions, enabled by AI. He was also Chair of the 2023 New Zealand Government's Start Up Advisors Council, established to help identify and address the opportunities and challenges facing high growth start-up businesses. Phil has over 20 years of experience investing into New Zealand technology companies and helping to guide their growth. He was an early investor in Trade Me, New Zealand's on-line trading community, which was sold to Fairfax in 2006. Phil was also an early investor into PowerByProxi, a wireless power technology spin-out from Auckland University, which was sold to Apple in 2018. Outside of Movac, Phil remains an active angel investor and maintains a personal angel investment portfolio. He is an advocate for the development of the entrepreneurial and early-stage investment eco-system in New Zealand and was the past Chair of the Angel Association of New Zealand. Prior to starting Movac, Phil spent 10 years with Deloitte Consulting working in New Zealand and the US.

Mr McLean has over 25 years of experience serving as chair, director, or an executive of research and technology businesses for both commercial and New Zealand Government organizations. In addition to AROA, Jim is also Chair of Prevar Limited. He was Chair of the New Zealand Institute of Plant & Food Research and Chair of its predecessor HortResearch, as well as several private businesses and start-up companies. He served on the board of the then Foundation for Research, Science, and Technology, including five years as Deputy Chair. Jim was an executive and director of Genesis Research & Development Corporation Limited during its early stages through to public listing. Before specializing in science and technology businesses, Jim held management positions with an international manufacturing business and spent thirteen years as a partner at chartered accountants, EY. His time at EY was focused on business strategy and included two years of secondment to EY's Washington DC office.

Mr Pinion has over 30 years of experience leading biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe and the Americas. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. John is also an advisory board member for Celestial Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation novel and ground-breaking mRNA vaccines and therapeutics for the treatment and prevention of a variety of infectious diseases, rare diseases and cancers. John has previously held operational and senior leadership roles in Genentech (subsequently Roche post Genentech acquisition), as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations) and Baxter Internationals Renal, Bioscience, Parenterals and Device divisions. He is a Chair of the Risk Committee.

Mr Ward has held senior corporate roles in life sciences and health care companies for more than 25 years. He has management experience in life science companies spanning clinical, technical, sales, marketing, corporate development and strategy having worked for several multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, and has sat on several government and industry expert panels.

Ms Mohr has over 30 years of experience across a diverse range of fields, including engineering, healthcare, alternative energy, aerospace and global entrepreneurship. She has been President of the Intuitive Foundation since 2018. Prior to leading the Foundation, Catherine held senior roles at Intuitive Surgical, including Vice President of Strategy and Director of Medical Research. Catherine is also on the board of directors for FINCA International and cofounded VeriSure, where she invented the LapCap, the first of a new category of laparoscopic surgery enabling products. She is a member of the Risk Committee.

Ms Hutton has more than 25 years of medical technology experience, including global leadership expertise in commercial strategy, operations, sales, marketing, healthcare analytics, lean and enterprise consulting. Darla is currently vice president, Asia commercial operations and marketing at Intuitive, pioneers in the field of robotic-assisted surgery and maker of the da Vinci surgical and ION diagnostic robot systems. Throughout her tenure at Intuitive, Darla has held commercial roles of increasing responsibility including Regional Sales Director, Vice President of Corporate Accounts-US, and Vice President Marketing, Market Access & Custom Hospital Analytics. In addition, Darla has served as a member of Intuitive's Inclusion and Diversity Executive Council. Prior to Intuitive, Darla held commercial positions at other medical technology, pharmaceutical, and biotech companies, including Boston Scientific and GlaxoSmithKline, and spent her early professional career in the cardiac-thoracic nursing field. She is a member of the Risk Committee.

-

-

-

-

-

-

-